Facilitated monocyte-macrophage uptake and tissue distribution of superparmagnetic iron-oxide nanoparticles

PLoS ONE

Volumn 4, Issue 2, 2009, Pages

  Beduneau, Arnaud ^a,b   Ma, Zhiya ^a,b   Grotepas, Cassi B ^a,b   Kabanov, Alexander ^a,c   Rabinow, Barrett E ^d   Gong, Nan ^a,b   Mosley, R Lee ^a,b,c   Dou, Huanyu ^a,b,c   Boska, Michael D ^b,c   Gendelman, Howard E ^a,b,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; SPIOFERIDEX; SUPERPARAMAGNETIC IRON OXIDE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STRUCTURE; CELL TRANSPORT; CELL VIABILITY; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; COVALENT BOND; DOSE TIME EFFECT RELATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; HUMAN CELL; MACROPHAGE; MALE; MATERIAL COATING; MONOCYTE; MONONUCLEAR PHAGOCYTE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPSONIZATION; OPTICAL DENSITY; OXIDATION; PARTICLE SIZE; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION;

ALEXA; ANIMALIA; MURINAE; MUS;

EID: 84887212497     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004343     Document Type: Article

References (39)

1. Kingsley JD, Dou H, Morehead J, Rabinow B, Gendelman HE, et al. (2006) Nanotechnology: a focus on nanoparticles as a drug delivery system. J Neuroimmune Pharmacol 1: 340-350.
2. Zhu T, Muthui D, Holte S, Nickle D, Feng F, et al. (2002) Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J Virol 76: 707-716.
3. Dou H, Destache CJ, Morehead JR, Mosley RL, Boska MD, et al. (2006) Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood 108: 2827-2835.
4. Gorantla S, Dou H, Boska M, Destache CJ, Nelson J, et al. (2006) Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery. J Leukoc Biol 80: 1165-1174.
5. Dou H, Morehead J, Destache CJ, Kingsley JD, Shlyakhtenko L, et al. (2007) Laboratory investigations for the morphologic, pharmacokinetic, and antiretroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology 358: 148-158.
6. Nelson JA, Dou H, Ellison B, Uberti M, Xiong H, et al. (2005) Coregistration of quantitative proton magnetic resonance spectroscopic imaging with neuropathological and neurophysiological analyses defines the extent of neuronal impairments in murine human immunodeficiency virus type-1 encephalitis. J Neurosci Res 80: 562-575.
7. Pereboeva L, Curiel DT (2004) Cellular vehicles for cancer gene therapy: current status and future potential. BioDrugs 18: 361-385.
8. Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE (2008) Preclinical Studies To Understand Nanoparticle Interaction with the Immune System and Its Potential Effects on Nanoparticle Biodistribution. Mol Pharm.
9. Choi MR, Stanton-Maxey KJ, Stanley JK, Levin CS, Bardhan R, et al. (2007) A cellular Trojan Horse for delivery of therapeutic nanoparticles into tumors. Nano Lett 7: 3759-3765.
10. Kuwata T, Kodama M, Sato A, Suzuki H, Miyazaki Y, et al. (2007) Contribution of monocytes to viral replication in macaques during acute infection with simian immunodeficiency virus. AIDS Res Hum Retroviruses 23: 372-380.
11. Zelivyanskaya ML, Nelson JA, Poluektova L, Uberti M, Mellon M, et al. (2003) Tracking superparamagnetic iron oxide labeled monocytes in brain by high-field magnetic resonance imaging. J Neurosci Res 73: 284-295.
12. Dutta T, Agashe HB, Garg M, Balakrishnan P, Kabra M, et al. (2007) Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro. J Drug Target 15: 89-98.
13. Owen MR, Byrne HM, Lewis CE (2004) Mathematical modelling of the use of macrophages as vehicles for drug delivery to hypoxic tumour sites. J Theor Biol 226: 377-391.
14. Engberink RD, Blezer EL, Hoff EI, van der Pol SM, van der Toorn A, et al. (2008) MRI of monocyte infiltration in an animal model of neuroinflammation using SPIO-labeled monocytes or free USPIO. J Cereb Blood Flow Metab 28: 841-851.
15. Mehta K, Lopez-Berestein G, Hersh EM, Juliano RL (1982) Uptake of liposomes and liposome-encapsulated muramyl dipeptide by human peripheral blood monocytes. J Reticuloendothel Soc 32: 155-164.
16. Thiele L, Rothen-Rutishauser B, Jilek S, Wunderli-Allenspach H, Merkle HP, et al. (2001) Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages? J Control Release 76: 59-71.
17. Moghimi SM, Hunter AC (2001) Capture of stealth nanoparticles by the body's defences. Crit Rev Ther Drug Carrier Syst 18: 527-550.
18. Moghimi SM, Szebeni J (2003) Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 42: 463-478.
19. Riemer J, Hoepken HH, Czerwinska H, Robinson SR, Dringen R (2004) Colorimetric ferrozine-based assay for the quantitation of iron in cultured cells. Anal Biochem 331: 370-375.
20. Kadiu I, Glanzer JG, Kipnis J, Gendelman HE, Thomas MP (2005) Mononuclear phagocytes in the pathogenesis of neurodegenerative diseases. Neurotox Res 8: 25-50.
21. Ciborowski P, Gendelman HE (2006) Human immunodeficiency virus-mononuclear phagocyte interactions: emerging avenues of biomarker discovery, modes of viral persistence and disease pathogenesis. Curr HIV Res 4: 279-291.
22. Betageri GV, Black CD, Szebeni J, Wahl LM, Weinstein JN (1993) Fc-receptor-mediated targeting of antibody-bearing liposomes containing dideoxycytidine triphosphate to human monocyte/macrophages. J Pharm Pharmacol 45: 48-53.
23. Holevinsky KO, Nelson DJ (1998) Membrane capacitance changes associated with particle uptake during phagocytosis in macrophages. Biophys J 75: 2577-2586.
24. Pietruska M, Zak J, Pietruski J, Wysocka J (2006) Evaluation of mCD14 expression on monocytes and the blood level of sCD14 in patients with generalized aggressive periodontitis. Adv Med Sci 51 Suppl 1: 166-169.
25. Daleke DL, Hong K, Papahadjopoulos D (1990) Endocytosis of liposomes by macrophages: binding, acidification and leakage of liposomes monitored by a new fluorescence assay. Biochim Biophys Acta 1024: 352-366.
26. Fujiwara H, Aotani T, Tsuyuguchi I (1996) [From the immunological aspect-interleukin-10 production by human blood mononuclear cells stimulated with multidrug-resistant Mycobacterium tuberculosis]. Kekkaku 71: 43-46.
27. Jain S, Mishra V, Singh P, Dubey PK, Saraf DK, et al. (2003) RGD-anchored magnetic liposomes for monocytes/neutrophils-mediated brain targeting. Int J Pharm 261: 43-55.
28. Perry VH, Bell MD, Brown HC, Matyszak MK (1995) Inflammation in the nervous system. Curr Opin Neurobiol 5: 636-641.
29. Khan MA, Jabeen R, Nasti TH, Mohammad O (2005) Enhanced anticryptococcal activity of chloroquine in phosphatidylserine-containing liposomes in a murine model. J Antimicrob Chemother 55: 223-228.
30. Audran R, Collet B, Moisan A, Toujas L (1995) Fate of mouse macrophages radiolabelled with PKH-95 and injected intravenously. Nucl Med Biol 22: 817-821.
31. Carver LA, Schnitzer JE (2003) Caveolae: mining little caves for new cancer targets. Nat Rev Cancer 3: 571-581.
32. Owens DE 3rd, Peppas NA (2006) Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 307: 93-102.
33. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V (2002) Rapid endolysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J 16: 1217-1226.
34. Manjunath K, Venkateswarlu V (2006) Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration. J Drug Target 14: 632-645.
35. Campbell RB (2006) Tumor physiology and delivery of nanopharmaceuticals. Anticancer Agents Med Chem 6: 503-512.
36. Paul M, Durand R, Boulard Y, Fusai T, Fernandez C, et al. (1998) Physicochemical characteristics of pentamidine-loaded polymethacrylate nanoparticles: implication in the intracellular drug release in Leishmania major infected mice. J Drug Target 5: 481-490.
37. Oude Engberink RD, van der Pol SM, Dopp EA, de Vries HE, Blezer EL (2007) Comparison of SPIO and USPIO for in vitro labeling of human monocytes: MR detection and cell function. Radiology 243: 467-474.
38. Connor RI, Dinces NB, Howell AL, Romet-Lemonne JL, Pasquali JL, et al. (1991) Fc receptors for IgG (Fc gamma Rs) on human monocytes and macrophages are not infectivity receptors for human immunodeficiency virus type 1 (HIV-1): studies using bispecific antibodies to target HIV-1 to various myeloid cell surface molecules, including the Fc gamma R. Proc Natl Acad Sci U S A 88: 9593-9597.
39. Nishikawa K, Arai H, Inoue K (1990) Scavenger receptor-mediated uptake and metabolism of lipid vesicles containing acidic phospholipids by mouse peritoneal macrophages. J Biol Chem 265: 5226-5231.